NEW YORK (GenomeWeb News) - Genizon Biosciences and pharmaceutical giant Pfizer have reached a licensing and collaboration agreement that gives Pfizer diagnostic rights to Genizon's research programs in Alzheimer's, attention deficit hyperactivity disorder, and endometriosis.
Pfizer has agreed to pay Genizon upfront license fees and will also fund the company’s research on genetic variations associated with those diseases. Pfizer will also buy an equity stake in the company, subject to certain closing conditions.
Genizon retains therapeutic rights to the research programs.
The companies will collaborate on the discovery of diagnostic markers based on Genizon’s ongoing genome-wide association studies of the Quebec Founder Population. Genizon said that the "unique genetic heritage" of the Quebec Founder Population offers opportunities to find genetic markers to predict disease susceptibility.
The companies plan to compare the data derived from these studies against data from other genome-wide association studies from conducted in "general populations."